2025
Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
Othus M, Kurzrock R, Patel S, Chae Y, Patel S, Sosman J, Snyder Charen A, Rizvi N, LaVallee T, Felquate D, Burton E, Futreal P, Sullivan R, Kluger H, Tawbi H. Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG. Journal Of Clinical Oncology 2025, 43: 2656-2656. DOI: 10.1200/jco.2025.43.16_suppl.2656.Peer-Reviewed Original ResearchOverall survivalMartingale residual plotsAdjuvant settingPD-(L)1Shorter OSNo significant differencePrimary resistanceAssociated with significantly shorter OSHazard ratioHigh-risk resected stagePD-(L)1 inhibitorsImmunotherapy of cancerSignificant differenceConfidence intervalsCox regression modelsClinical trial interpretationAdjuvant cohortAdjuvant pembrolizumabImmunotherapy resistanceLate recurrenceResected stageEarly recurrenceSWOG trialsIO agentsPatient cohort
1998
MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. Journal Of Urology 1998, 160: 1220-1229. PMID: 9751323, DOI: 10.1016/s0022-5347(01)62501-1.Peer-Reviewed Original ResearchConceptsTreatment of hormone refractory prostate cancerHormone refractory prostate cancerRefractory prostate cancerBiology of hormone refractory prostate cancerSecondary hormonal therapyProstate cancerHormone therapyProstate specific antigen valuesAntiandrogen withdrawal responsePhase II studyMeasurement of response to therapyResponse to therapyClinical trial endMeasure response to treatmentResponse to treatmentMEDLINE literature searchCombination of drugsClinical trial interpretationAvailability of agentsAlternative antiandrogenEstramustine combinationsPalliative capabilitiesClinical responsePalliative benefitII studyMANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER
OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. Journal Of Urology 1998, 160: 1220-1229.. DOI: 10.1097/00005392-199810000-00003.Peer-Reviewed Original ResearchTreatment of hormone refractory prostate cancerHormone refractory prostate cancerRefractory prostate cancerBiology of hormone refractory prostate cancerSecondary hormonal therapyProstate cancerHormone therapyProstate specific antigen valuesAntiandrogen withdrawal responsePhase II studyMeasurement of response to therapyResponse to therapyClinical trial endResponse to treatmentMeasure response to treatmentMEDLINE literature searchCombination of drugsClinical trial interpretationAvailability of agentsAlternative antiandrogenEstramustine combinationsPalliative capabilitiesClinical responsePalliative benefitII study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply